Scholars Central

Editorial Board Member

Charles Q Liu

Astellas Pharma Global Development, USA, Astellas Pharma US, Inc.

About

As published by the journal they serve.

Charles (Qianyong) Liu has over teen years of experience in biomarker R&D in oncology, CNS and cardiac diseases. Currently he is Principal Scientist at Astellas Pharma Global Development, responsible for developing and implementing translational biomarkers and delivering personalized medicine to support clinical trials in oncology and other therapeutic areas. He was Senior Research Scientist at Abraxis/Celgene where he served as tumor biomarker scientist and animal study manager in preclinical pipeline development. He completed his postdoctoral training in molecular genetics from Yale University and Howard Hughes Medical Institute. Dr. Liu received his PhD degree in Physiology from Cornell University and he is currently board certified by American Board of Toxicology and the Regulatory Affairs Professional Society.

Journals they serve

The seats these journals name them in.

Articles we hold

Articles in the journals they serve whose byline carries this name.

No article in our collection carries this name on its byline. Not every article names its authors in a way that can be matched, so this is not a list of everything they have written.

This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.